Treatment of T-PLL comparing patients treated first line, either with IV or SC alemtuzumab, with those treated with relapsed or refractory disease (N = 86)22
| . | First-line IV . | First-line SC . | Relapsed/refractory IV . |
|---|---|---|---|
| No. of patients | 32 | 9 | 45 |
| ORR, % | 91 | 33* | 74 |
| CR, % | 81 | 33* | 60 |
| PFS at 12 mo, % | 67 | 67 | 26 |
| HSCT, % | 50 | 55 | 30 |
| OS at 48 mo, % | 37 | 33 | 18 |
| . | First-line IV . | First-line SC . | Relapsed/refractory IV . |
|---|---|---|---|
| No. of patients | 32 | 9 | 45 |
| ORR, % | 91 | 33* | 74 |
| CR, % | 81 | 33* | 60 |
| PFS at 12 mo, % | 67 | 67 | 26 |
| HSCT, % | 50 | 55 | 30 |
| OS at 48 mo, % | 37 | 33 | 18 |
IV indicates intravenous; SC, subcutaneous; CR, complete remission; PR, partial remission; ORR, overall response rate; PFS, progression-free survival; HSCT, hematopoietic stem cell transplant; and OS, overall survival.
Increased to 67% when changed to IV and/or pentostatin added, but 2 of 9 patients died while on treatment.